Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CINDY E OWEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1598803819
CMS profile
117868
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,014.27

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $914.28 66
Education $99.99 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CINDY E OWEN

NPI 1598803819 · CMS profile ID 117868

Allopathic & Osteopathic Physicians / Dermatology

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598803819?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598803819?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CINDY E OWEN, NPI 1598803819, CMS profile ID 117868. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598803819?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CINDY E OWEN, NPI 1598803819, CMS profile ID 117868, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1598803819?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $1,014.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $19.2612/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813134841 CMS
AbbVie Inc. $14.9812/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458319 CMS
AbbVie Inc. $7.7012/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458313 CMS
Lilly USA, LLC $12.7012/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819028941 CMS
AbbVie Inc. $17.8411/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458307 CMS
AbbVie Inc. $19.1211/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458301 CMS
AbbVie Inc. $20.9911/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458295 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $15.7511/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849549183 CMS
LEO Pharma Inc. $21.1411/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842238675 CMS
GENZYME CORPORATION $21.8411/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843637293 CMS
AbbVie Inc. $17.5110/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458289 CMS
AbbVie Inc. $4.5210/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458283 CMS
GENZYME CORPORATION $16.1910/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843637291 CMS
Lilly USA, LLC $12.3410/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819017609 CMS
AbbVie Inc. $21.7910/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458277 CMS
Janssen Biotech, Inc. $20.0310/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788456905 CMS
Novartis Pharmaceuticals Corporation $13.3909/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813134837 CMS
AbbVie Inc. $19.5409/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458269 CMS
Janssen Biotech, Inc. $8.9909/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788456900 CMS
LEO Pharma Inc. $14.8109/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842238665 CMS
AbbVie Inc. $17.1108/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458263 CMS
Lilly USA, LLC $11.2108/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819016691 CMS
AbbVie Inc. $15.2608/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458257 CMS
AbbVie Inc. $7.3408/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458245 CMS
AbbVie Inc. $10.9408/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458251 CMS
GENZYME CORPORATION $18.8608/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843637253 CMS
Janssen Biotech, Inc. $9.7608/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788456895 CMS
Lilly USA, LLC $11.6408/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819018275 CMS
AbbVie Inc. $7.6307/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458239 CMS
Regeneron Healthcare Solutions, Inc. $13.1707/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809610747 CMS
AbbVie Inc. $16.0807/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458233 CMS
GENZYME CORPORATION $20.2107/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843637245 CMS
Janssen Biotech, Inc. $7.4107/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788456932 CMS
AbbVie Inc. $23.6607/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458227 CMS
AbbVie Inc. $17.1606/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458221 CMS
Lilly USA, LLC $18.7306/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819030311 CMS
Janssen Biotech, Inc. $4.5006/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788456891 CMS
Regeneron Healthcare Solutions, Inc. $15.5806/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809610745 CMS
LEO Pharma Inc. $12.7606/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842238657 CMS
AbbVie Inc. $19.7606/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458215 CMS
AbbVie Inc. $15.8206/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458209 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $14.2306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849549179 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $12.8806/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849549181 CMS
AbbVie Inc. $23.9406/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458203 CMS
AbbVie Inc. $12.1705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458197 CMS
Janssen Biotech, Inc. $3.3105/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788456927 CMS
Novartis Pharmaceuticals Corporation $14.6305/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813134833 CMS
AbbVie Inc. $8.9005/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795458191 CMS
Regeneron Healthcare Solutions, Inc. $16.6705/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809610743 CMS
Janssen Biotech, Inc. $6.3305/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788456887 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,410.66 70
PY2020 $4,329.13 26
PY2021 $1,014.27 67
PY2022 $1,019.13 72
PY2023 $883.07 50
PY2024 $1,269.36 78
PY2025 $1,140.98 54

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $848,779.58 205
PY2024 Principal investigator $465,404.25 284
PY2023 Principal investigator $512,761.61 145
PY2022 Recipient $8.00 1
PY2022 Principal investigator $318,333.10 76
PY2021 Recipient $579.11 2
PY2021 Principal investigator $303,603.63 109
PY2020 Recipient $5,811.05 7
PY2020 Principal investigator $509,738.55 72
PY2019 Recipient $47,562.83 13
PY2019 Principal investigator $1,244,974.63 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

145 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Acrotech Biopharma Inc. $1,500.00 12/29/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-302 No dispute reported 06/30/2026 1053741547
Principal investigator 1 SANOFI US SERVICES INC. $1,654.48 12/18/2023 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1035946627
Principal investigator 1 Padagis US LLC $5,500.00 12/07/2023 Non-covered Recipient Entity
Scott Health Services, LLC
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis Israel Pharmaceuticals, Ltd. Roflumilast Cream 0.3% to Arcutis Biotherapeutics, Inc. Zoryve (Roflumilast Cream 0.3%) Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1060528813
Principal investigator 1 Padagis US LLC $17,100.00 12/07/2023 Non-covered Recipient Entity
Scott Health Services, LLC
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis Israel Pharmaceuticals, Ltd. Roflumilast Cream 0.3% to Arcutis Biotherapeutics, Inc. Zoryve (Roflumilast Cream 0.3%) Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1060528815
Principal investigator 1 Padagis US LLC $21,420.00 12/07/2023 Non-covered Recipient Entity
Scott Health Services, LLC
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis Israel Pharmaceuticals, Ltd. Roflumilast Cream 0.3% to Arcutis Biotherapeutics, Inc. Zoryve (Roflumilast Cream 0.3%) Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1060528817
Principal investigator 1 Padagis US LLC $14,220.00 12/07/2023 Non-covered Recipient Entity
Scott Health Services, LLC
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis Israel Pharmaceuticals, Ltd. Roflumilast Cream 0.3% to Arcutis Biotherapeutics, Inc. Zoryve (Roflumilast Cream 0.3%) Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1060528819
Principal investigator 1 Padagis US LLC $6,810.00 12/07/2023 Non-covered Recipient Entity
Scott Health Services, LLC
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis Israel Pharmaceuticals, Ltd. Roflumilast Cream 0.3% to Arcutis Biotherapeutics, Inc. Zoryve (Roflumilast Cream 0.3%) Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1060528821
Principal investigator 1 Padagis US LLC $1,150.00 12/07/2023 Non-covered Recipient Entity
Scott Health Services, LLC
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis Israel Pharmaceuticals, Ltd. Roflumilast Cream 0.3% to Arcutis Biotherapeutics, Inc. Zoryve (Roflumilast Cream 0.3%) Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1060528823
Principal investigator 1 Padagis US LLC $2,990.00 12/07/2023 Non-covered Recipient Entity
Scott Health Services, LLC
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis Israel Pharmaceuticals, Ltd. Roflumilast Cream 0.3% to Arcutis Biotherapeutics, Inc. Zoryve (Roflumilast Cream 0.3%) Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1060528827
Principal investigator 1 Padagis US LLC $1,000.00 12/07/2023 Non-covered Recipient Entity
Scott Health Services, LLC
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis Israel Pharmaceuticals, Ltd. Roflumilast Cream 0.3% to Arcutis Biotherapeutics, Inc. Zoryve (Roflumilast Cream 0.3%) Cream and Both Active Treatments to a Vehicle Control in the Treatment of Plaque Psoriasis No dispute reported 06/30/2026 1060528829
Principal investigator 1 Incyte Corporation $1,216.90 12/04/2023 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040725495
Principal investigator 1 Incyte Corporation $2,402.00 12/04/2023 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040725509
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 11/29/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993570187
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 11/28/2023 Non-covered Recipient Entity
DS RESEARCH OF KENTUCKY LLC
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period No dispute reported 06/30/2026 1039783363
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $500.00 11/21/2023 Non-covered Recipient Entity
Scott Health Services
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053796957
Principal investigator 1 Acrotech Biopharma Inc. $22,050.45 11/09/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-302 No dispute reported 06/30/2026 1053741301
Principal investigator 1 CSL Behring $478.56 11/09/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1042915943
Principal investigator 1 Incyte Corporation $1,408.50 11/06/2023 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040724051
Principal investigator 1 Amgen Inc. $6,298.88 11/02/2023 Non-covered Recipient Entity
DS RESEARCH
P3 AD Extension No dispute reported 06/30/2026 1029654495
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $13,245.30 11/01/2023 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053796925
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 10/31/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568551
Principal investigator 1 Incyte Corporation $1,652.40 10/11/2023 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040724015
Principal investigator 1 Incyte Corporation $1,604.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040724037
Principal investigator 1 Incyte Corporation $2,266.00 10/11/2023 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040725525
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 10/10/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567057
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 10/10/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567059
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 10/10/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567061
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 10/10/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567063
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $250.00 10/09/2023 Non-covered Recipient Entity
Scott Health Services
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053796945
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $500.00 10/09/2023 Non-covered Recipient Entity
Scott Health Services
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053796969
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,500.00 10/09/2023 Non-covered Recipient Entity
Scott Health Services
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053796981
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $500.00 10/09/2023 Non-covered Recipient Entity
Scott Health Services
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053796991
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,500.00 10/09/2023 Non-covered Recipient Entity
Scott Health Services
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053797001
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,000.00 10/09/2023 Non-covered Recipient Entity
Scott Health Services
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053797011
Principal investigator 1 SANOFI US SERVICES INC. $500.00 09/26/2023 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1035950635
Principal investigator 1 SANOFI US SERVICES INC. $750.00 09/21/2023 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1035950509
Principal investigator 1 Dermavant Sciences, Inc. $49.14 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563857
Principal investigator 1 Dermavant Sciences, Inc. $49.14 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563859
Principal investigator 1 Dermavant Sciences, Inc. $49.14 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563861
Principal investigator 1 Dermavant Sciences, Inc. $49.14 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563863
Principal investigator 1 Dermavant Sciences, Inc. $49.14 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563865
Principal investigator 1 Dermavant Sciences, Inc. $49.14 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563867
Principal investigator 1 Dermavant Sciences, Inc. $227.14 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563869
Principal investigator 1 Dermavant Sciences, Inc. $227.14 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563871
Principal investigator 1 Dermavant Sciences, Inc. $227.14 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563873
Principal investigator 1 Dermavant Sciences, Inc. $227.14 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563875
Principal investigator 1 Dermavant Sciences, Inc. $227.14 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563877
Principal investigator 1 Dermavant Sciences, Inc. $220.32 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563879
Principal investigator 1 Dermavant Sciences, Inc. $220.32 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563881
Principal investigator 1 Dermavant Sciences, Inc. $220.32 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563883
Principal investigator 1 Dermavant Sciences, Inc. $177.22 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563885
Principal investigator 1 Dermavant Sciences, Inc. $177.22 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563887
Principal investigator 1 Dermavant Sciences, Inc. $177.22 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563889
Principal investigator 1 Dermavant Sciences, Inc. $177.22 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563891
Principal investigator 1 Dermavant Sciences, Inc. $177.22 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563893
Principal investigator 1 Dermavant Sciences, Inc. $177.22 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563895
Principal investigator 1 Dermavant Sciences, Inc. $212.52 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563897
Principal investigator 1 Dermavant Sciences, Inc. $212.52 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563899
Principal investigator 1 Dermavant Sciences, Inc. $212.52 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563901
Principal investigator 1 Dermavant Sciences, Inc. $212.52 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563903
Principal investigator 1 Dermavant Sciences, Inc. $212.52 09/12/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993563905
Principal investigator 1 Acrotech Biopharma Inc. $7,155.45 09/07/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-301 No dispute reported 06/30/2026 1053741129
Principal investigator 1 Acrotech Biopharma Inc. $11,860.65 09/07/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-302 No dispute reported 06/30/2026 1053741147
Principal investigator 1 Incyte Corporation $4,899.60 09/06/2023 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040723903
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 08/25/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563187
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 08/25/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563189
Principal investigator 1 Eli Lilly and Company $6.30 08/22/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED OPERATIONALLY SEAMLESS ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1038128135
Principal investigator 1 SANOFI US SERVICES INC. $1,854.40 08/21/2023 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1035946525
Principal investigator 1 Incyte Corporation $12,311.10 08/09/2023 Non-covered Recipient Entity
DERMATOLOGIST SPECIALIST
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040723885
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 07/14/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559583
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 07/14/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559585
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 07/14/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559587
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $22,402.80 07/14/2023 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053796913
Principal investigator 1 Acrotech Biopharma Inc. $13,829.40 07/13/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-302 No dispute reported 06/30/2026 1053740975
Principal investigator 1 Acrotech Biopharma Inc. $65,350.35 06/29/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-301 No dispute reported 06/30/2026 1053740939
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 06/23/2023 Non-covered Recipient Entity
Scott Hlth Svcs Llc
CNTO1959PSO3018 No dispute reported 06/30/2026 986114947
Principal investigator 1 Janssen Research & Development, LLC $750.00 06/22/2023 Non-covered Recipient Entity
Scott Hlth Svcs Llc
CNTO1959PSO3018 No dispute reported 06/30/2026 986114941
Principal investigator 1 Janssen Research & Development, LLC $500.00 06/22/2023 Non-covered Recipient Entity
Scott Hlth Svcs Llc
CNTO1959PSO3018 No dispute reported 06/30/2026 986114943
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 06/10/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558601
Principal investigator 1 Eli Lilly and Company $15,352.00 06/06/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED OPERATIONALLY SEAMLESS ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1038139579
Principal investigator 1 Janssen Research & Development, LLC $6,000.00 06/06/2023 Non-covered Recipient Entity
Scott Hlth Svcs Llc
CNTO1959PSO3018 No dispute reported 06/30/2026 986114945
Principal investigator 1 Amgen Inc. $4,133.64 06/01/2023 Non-covered Recipient Entity
DS RESEARCH
P3 AD Monotherapy Induction No dispute reported 06/30/2026 1029654885
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 05/19/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557381
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 05/19/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557383
Principal investigator 1 Journey Medical Corporation $1,800.00 05/17/2023 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, PLLC
DFD-29-CD-005 No dispute reported 06/30/2026 1054449329
Principal investigator 1 SANOFI US SERVICES INC. $5,088.90 05/15/2023 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1035946463
Principal investigator 1 CSL Behring $7.84 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938071
Principal investigator 1 CSL Behring $9.41 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938073
Principal investigator 1 CSL Behring $31.13 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938075
Principal investigator 1 CSL Behring $308.00 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938077
Principal investigator 1 CSL Behring $314.38 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938079
Principal investigator 1 CSL Behring $690.68 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938081
Principal investigator 1 CSL Behring $365.68 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938083
Principal investigator 1 CSL Behring $755.48 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938085
Principal investigator 1 CSL Behring $987.48 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938087
Principal investigator 1 CSL Behring $1,574.92 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938089
Principal investigator 1 CSL Behring $963.69 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938091
Principal investigator 1 CSL Behring $2,975.12 05/03/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1057938093
Principal investigator 1 Janssen Research & Development, LLC $1,926.00 05/01/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 986143739
Principal investigator 1 CSL Behring $359.32 04/21/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1042915901
Principal investigator 1 Acrotech Biopharma Inc. $7,449.30 04/20/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-302 No dispute reported 06/30/2026 1053740737
Principal investigator 1 CSL Behring $785.79 04/20/2023 Non-covered Recipient Entity
DS RESEARCH
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) No dispute reported 06/30/2026 1042915885
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $19,388.25 04/20/2023 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053796901
Principal investigator 1 Dermavant Sciences, Inc. $198.35 04/13/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554603
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 04/13/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554605
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 04/13/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554607
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 04/13/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554609
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 04/13/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993554695
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,801.35 04/12/2023 Non-covered Recipient Entity
Scott Health Services
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053797033
Principal investigator 1 GENZYME CORPORATION $821.37 04/04/2023 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 1035946441
Principal investigator 1 GENZYME CORPORATION $36.00 04/04/2023 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 1035946453
Principal investigator 2 Arcutis Biotherapeutics, Inc. $1,250.00 04/03/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044811337
Principal investigator 2 Arcutis Biotherapeutics, Inc. $1,250.00 04/03/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044811405
Principal investigator 1 Janssen Research & Development, LLC $5,796.00 03/27/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 986143733
Principal investigator 1 SANOFI US SERVICES INC. $1,334.20 03/27/2023 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) No dispute reported 06/30/2026 1035946431
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $500.00 03/14/2023 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053796859
Principal investigator 1 GENZYME CORPORATION $612.00 03/06/2023 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 1035946391
Principal investigator 1 Eli Lilly and Company $6,030.00 03/03/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1038139569
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $5,653.17 03/03/2023 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056327183
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,000.00 03/01/2023 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053796881
Principal investigator 1 Acrotech Biopharma Inc. $3,177.90 02/24/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
246-13651-302 No dispute reported 06/30/2026 1053740377
Principal investigator 1 Janssen Research & Development, LLC $5,778.00 02/23/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 986143735
Principal investigator 1 Dermavant Sciences, Inc. $198.35 02/16/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551031
Principal investigator 1 Dermavant Sciences, Inc. $937.98 02/16/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551033
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 02/16/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993551035
Principal investigator 1 Dermavant Sciences, Inc. $278.46 02/16/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551105
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 02/16/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993551107
Principal investigator 1 Arcutis Biotherapeutics, Inc. $500.00 02/13/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044811167
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $500.00 02/09/2023 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053796871
Principal investigator 1 Eli Lilly and Company $1,696.26 02/08/2023 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS RESEARCH
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED OPERATIONALLY SEAMLESS ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1038107751
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $22,331.20 02/08/2023 Non-covered Recipient Entity
Scott Health Services
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) No dispute reported 06/30/2026 1053796935
Principal investigator 1 GENZYME CORPORATION $4,405.34 02/06/2023 Non-covered Recipient Entity
Scott Health Services Llc Ds Research
POC - Atopic dermatitis No dispute reported 06/30/2026 1035946361
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $15,926.40 02/01/2023 Non-covered Recipient Entity
Scott Health Services
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053796891
Principal investigator 1 Janssen Research & Development, LLC $7,887.00 01/30/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 986143737
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $500.00 01/26/2023 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056327127
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $105.00 01/26/2023 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056327145
Principal investigator 1 Kiniksa Pharmaceuticals, Ltd. $800.00 01/26/2023 Non-covered Recipient Entity
Associates In Dermatology
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1056327165
Principal investigator 2 Arcutis Biotherapeutics, Inc. $500.00 01/23/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES, LLC
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1044811307
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,899.45 01/18/2023 Non-covered Recipient Entity
Scott Health Services
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053797023
Principal investigator 1 Dermavant Sciences, Inc. $937.98 01/10/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993549649
Principal investigator 1 Dermavant Sciences, Inc. $278.46 01/10/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549697
Principal investigator 1 Dermavant Sciences, Inc. $1,004.28 01/10/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549699
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 01/10/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549701
Principal investigator 1 Dermavant Sciences, Inc. $1,204.28 01/10/2023 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC DBA DS RESEARCH
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993549703
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,571.00 01/05/2023 Non-covered Recipient Entity
Dermatology Specialists Research-kentucky
Phase II Umbrella AD - A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1027448117